On the value of radiomics in addition to clinical measures in emotional conflict fMRI for predicting sertraline response in major depressive disorder
Abstract
Most patients with major depressive disorder (MDD) do not respond to first-line treatment, and robust predictors of individual outcomes are lacking. Functional MRI (fMRI) has shown promise for identifying treatment-relevant brain markers, but standard analyses often rely on mean activation within regions of interest (ROIs). Emotional-conflict fMRI elicits spatially heterogeneous, potentially clinically relevant activation, which radiomics can capture by quantifying the texture and distribution of voxel-wise activity. In this preregistered study, we tested whether radiomic features improved the prediction of treatment response compared to mean fMRI ROI activation at baseline (week 0) and early-treatment (week 1) of 254 MDD outpatients participating in the EMBARC RCT (123 sertraline, 131 placebo). Across models, clinical variables provided the strongest predictive signal, and imaging-only models showed limited predictive utility. Placebo but not sertraline response could be predicted at week 1 early-treatment with three combined models incorporating different levels of imaging information, although not at week 0 baseline. In our regression analysis, combined models including mean ROI features yielded modest performance for sertraline (baseline: r = 0.22; early-treatment: r = 0.29; P 0.05), whereas whole-brain models modestly improved prediction (baseline: r = 0.29; P = 0.0012). Early clinical measures remained the strongest predictors with higher importance than radiomic…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.